ChiCTR2500099033 版本V1.0 版本创建时间2025/03/18 08:35:56 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2500099033 

最近更新日期:

Date of Last Refreshed on:

2025-03-18 08:35:51 

注册时间:

Date of Registration:

2025-03-18 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

宫安康?用于人流术后子宫内膜修复作用的安全性和有效性:一项前瞻性、多中心、单臂临床研究

Public title:

Safety and efficacy of MateRegen? for endometrial repair after abortion: a prospective, multicenter, single-arm clinical study

注册题目简写:

English Acronym:

研究课题的正式科学名称:

宫安康?用于人流术后子宫内膜修复作用的安全性和有效性:一项前瞻性、多中心、单臂临床研究

Scientific title:

Safety and efficacy of MateRegen? for endometrial repair after abortion: a prospective, multicenter, single-arm clinical study

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

江静 

研究负责人:

江静 

Applicant:

Jing Jiang 

Study leader:

Jing Jiang 

申请注册联系人电话:

Applicant telephone:

+86 137 8030 7399

研究负责人电话:

Study leader's
telephone:

+86 137 8030 7399

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

jiangjing011@sina.com

研究负责人电子邮件:

Study leader's E-mail:

jiangjing011@sina.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

河北省石家庄市和平西路215号

研究负责人通讯地址:

河北省石家庄市和平西路215号

Applicant address:

No. 215, Heping West Road, Shijiazhuang, Hebei, China

Study leader's address:

No. 215, Heping West Road, Shijiazhuang, Hebei, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

河北医科大学第二医院

Applicant's institution:

The Second Hospital of Hebei Medical University

研究负责人所在单位:

河北医科大学第二医院

Affiliation of the Leader:

The Second Hospital of Hebei Medical University

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2024-C103

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

河北医科大学第二医院科研伦理委员会

Name of the ethic committee:

Research Ethics Committee of the second hospital of Hebei Medical University

伦理委员会批准日期:

Date of approved by ethic committee:

2024-12-16 00:00:00

伦理委员会联系人:

孙惠莲

Contact Name of the ethic committee:

Huilian Sun

伦理委员会联系地址:

河北省石家庄市和平西路215号

Contact Address of the ethic committee:

No. 215, Heping West Road, Shijiazhuang, Hebei, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 311 6600 2826

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

河北医科大学第二医院

Primary sponsor:

The Second Hospital of Hebei Medical University

研究实施负责(组长)单位地址:

石家庄市鹿泉区槐安西路501号

Primary sponsor's address:

No.501, Huai'an West Road, Luquan District, Shijiazhuang, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

河北

市(区县):

Country:

China

Province:

Hebei

City:

单位(医院):

河北医科大学第二医院

具体地址:

石家庄市鹿泉区槐安西路501号

Institution
hospital:

The Second Hospital of Hebei Medical University

Address:

No.501, Huai'an West Road, Luquan District, Shijiazhuang, China

经费或物资来源:

Source(s) of funding:

None

研究疾病:

子宫腔粘连  

Target disease:

Surgical Abortion

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

单臂 

Study design:

Single arm 

研究目的:

本临床研究的目的是对宫腔用交联透明质酸钠凝胶 (宫安康?)在人流手术后对子宫内膜修复作用的效果进行评价。  

Objectives of Study:

The purpose of this clinical study was to evaluate the effect of intrauterine cross-linked sodium hyaluronate gel (MateRegen?) on endometrial repair after abortion.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1. 经检查确定进行人流手术(负压吸引术)的患者; 2. 年龄18-45周岁; 3. 无严重系统性疾病; 4. 取得参加研究的知情同意书; 5. 依从性良好,术后愿意并且能够按要求进行随访观察; 6. 同时符合以下两条(1)孕周<10孕周;(2)术前超声提示胎囊≥1cm或胎芽<3.0cm。

Inclusion criteria

1. Patients who have been examined and determined to undergo abortion (negative pressure suction); 2. Aged 18-45 years old; 3. Without serious systemic diseases. 4. Obtain informed consent to participate in the study; 5. Have good compliance and are willing and able to follow up after the operation as required; 6. Meet the following two criteria: (1) gestational week <10 weeks; (2) preoperative ultrasound suggests that the fetal sac is >=1cm or the fetal bud is <3.0cm.

排除标准:

1. 合并其他妇科疾病(例如:子宫肌瘤、子宫腺肌病、宫腔粘连病史); 2. 合并严重心、肝、肾等重要脏器功能障碍; 3. 既往月经失调,多囊卵巢综合症; 4. 透明质酸过敏; 5. 其他研究者认为不符合入组的情况。

Exclusion criteria:

1. Combination of other gynecologic diseases (e.g., history of uterine fibroids, adenomyosis, uterine adhesions); 2. Comorbidity with severe cardiac, hepatic, renal and other vital organ dysfunction; 3. Pre-existing menstrual disorders, polycystic ovary syndrome; 4. Hyaluronic acid allergy; 5. Other conditions that the investigator considers ineligible for enrollment.

研究实施时间:

Study execute time:

From 2025-01-01 00:00:00 To 2025-12-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2025-03-22 00:00:00 To 2025-12-31 00:00:00

干预措施:

Interventions:

组别:

试验组

样本量:

500

Group:

Experimental group

Sample size:

干预措施:

宫腔用交联透明质酸钠凝胶

干预措施代码:

Intervention:

Cross-linked sodium hyaluronate gel

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

河北 

市(区县):

 

Country:

China

Province:

Hebei

City:

单位(医院):

河北医科大学第二医院 

单位级别:

三甲 

Institution
hospital:

The Second Hospital of Hebei Medical University

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

河北 

市(区县):

 

Country:

China

Province:

Hebei

City:

单位(医院):

石家庄市妇幼保健院 

单位级别:

三甲 

Institution
hospital:

Shijiazhuang Maternal and Child Health Center

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

河北 

市(区县):

 

Country:

China

Province:

Hebei

City:

单位(医院):

保定市妇幼保健院 

单位级别:

三甲 

Institution
hospital:

Baoding Maternal and Child Health Center

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

河北 

市(区县):

 

Country:

China

Province:

Hebei

City:

单位(医院):

沧州市妇幼保健院 

单位级别:

三甲 

Institution
hospital:

Cangzhou Maternal and Child Health Center

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

河北 

市(区县):

 

Country:

China

Province:

Hebei

City:

单位(医院):

邯郸市妇幼保健院 

单位级别:

三甲 

Institution
hospital:

Handan Maternal and Child Health Center

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

河北 

市(区县):

 

Country:

China

Province:

Hebei

City:

单位(医院):

唐山市妇幼保健院 

单位级别:

三甲 

Institution
hospital:

Tangshan Maternal and Child Health Center

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

河北 

市(区县):

 

Country:

China

Province:

Hebei

City:

单位(医院):

承德市妇幼保健院 

单位级别:

二甲 

Institution
hospital:

Chengde Maternal and Child Health Center

Level of the institution:

Secondary A

国家:

中国

省(直辖市):

河北 

市(区县):

 

Country:

China

Province:

Hebei

City:

单位(医院):

邢台市信都区中心医院 

单位级别:

二甲 

Institution
hospital:

Xingtai Xindu District Central Hospital

Level of the institution:

Secondary A

国家:

中国

省(直辖市):

河北 

市(区县):

 

Country:

China

Province:

Hebei

City:

单位(医院):

廊坊市妇幼保健院 

单位级别:

三甲 

Institution
hospital:

Langfang Maternal and Child Health Center

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

子宫内膜厚度

指标类型:

主要指标

Outcome:

Endometrial thickness

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

月经来潮时间

指标类型:

次要指标

Outcome:

Menstruation time

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

月经持续时间

指标类型:

次要指标

Outcome:

Duration of menstruation

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

月经量

指标类型:

次要指标

Outcome:

Menstrual volume

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

痛经

指标类型:

次要指标

Outcome:

Menstrual cramps

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

N/A

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 45 years

性别:

女性

Gender:

Female

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

N/A

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

Blinding:

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

N/A

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病历记录表

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

CRF

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2025-03-18 08:35:51